This retrospective observational study looked at 44 children with atypical ulcerative colitis (aUC) in Australia who received oral vancomycin (OV) therapy between 2014 – 2023. This study includes 29 children with both PSC and aUC and 15 children with aUC without PSC. Most of the children who received OV saw reduced UC activity and fecal […]
How Frequent Are Vancomycin-Resistant Enterococci in patients with Primary Sclerosing Cholangitis and Ulcerative Colitis Treated With Oral Vancomycin?
This study followed seven adult patients with both PSC and ulcerative colitis. All patients were treated for at least six months with oral vancomycin doses between 250 mg – 1,500 mg per day. All patients achieved clinical remission with their ulcerative colitis. Labs that decreased included: fecal calprotectin, C-reactive protein, the Mayo score, alkaline phosphatase, […]
Vancomycin for PSC Q&A with Dr. Davies: Presented by the Children’s PSC Foundation
In 2011, Dr. Yinka Davies, a pediatric gastroenterologist, held a teleconference call with the parents of children with PSC patients. The conversation was recorded into a written Q&A format. Topics cover: • Vancomycin safety, side effects, and vancomycin-resistant bacteria • The use of probiotics when taking vancomycin • The effect of vancomycin on other autoimmune […]